- Volume 13 Issue 5
DOI QR Code
ER81-shRNA Inhibits Growth of Triple-negative Human Breast Cancer Cell Line MDA-MB-231 In Vivo and in Vitro
- Chen, Yue (Department of Pathology, Kunming General Hospital) ;
- Zou, Hong (Department of Pathology, Kunming General Hospital) ;
- Yang, Li-Ying (Department of Pathology, Kunming General Hospital) ;
- Li, Yuan (Department of Pathology, Kunming General Hospital) ;
- Wang, Li (Department of Pathology, Kunming General Hospital) ;
- Hao, Yan (Department of Pathology, Kunming General Hospital) ;
- Yang, Ju-Lun (Department of Pathology, Kunming General Hospital)
- Published : 2012.05.30
The lack of effective treatment targets for triple-negative breast cancers make them unfitted for endocrine or HER2 targeted therapy, and their prognosis is poor. Transcription factor ER81, a downstream gene of the HER2, is highly expressed in breast cancer lines, breast atypical hyperplasia and primary breast cancers including triple-negative examples. However, whether and how ER81 affects breast cancer carcinogenesis have remained elusive. We here assessed influence on a triple-negative cell line. ER81-shRNA was employed to silence ER81 expression in the MDA-MB-231 cell line, and MTT, colony-forming assays, and flow cytometry were used to detect cell proliferation, colony-forming capability, cell cycle distribution, and cell apoptosis in vitro. MDA-MB-231 cells stably transfected with ER81-shRNA were inoculated into nude mice, and growth inhibition of the cells was observed in vivo. We found that ER81 mRNA and protein expression in MDA-MB-231 cells was noticeably reduced by ER81-shRNA, and that cell proliferation and clonality were decreased significantly. ER81-shRNA further increased cell apoptosis and the residence time in
- Baert JL, Monte D, Musgrove EA, et al (1997). Expression of the PEA3 group of ETS-related transcription factors in human breast-cancer cells. Int J Cancer, 70, 590-7. https://doi.org/10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H
- Bosc DG, Goueli BS, Janknecht R (2001). HER2/Neu-mediated activation of the ETS transcription factor ER81 and its target gene MMP-1. Oncogene, 20, 6215-24. https://doi.org/10.1038/sj.onc.1204820
- Bosc DG, Janknecht R (2002). Regulation of Her2/neu promoter activity by the ETS transcription factor, ER81. J Cell Biochem, 86, 174-83. https://doi.org/10.1002/jcb.10205
- Brown TA, McKnight SL (1992). Specificities of protein-protein and protein-DNA interaction of GABP alpha and two newly defined ets-related proteins. Genes Dev, 6, 2502-12. https://doi.org/10.1101/gad.6.12b.2502
- Cai C, Hsieh CL, Omwancha J, et al (2007). ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Mol Endocrinol, 21, 1835-46. https://doi.org/10.1210/me.2006-0480
- Chen W, Yuan K, Tao ZZ, et al (2011). Deletion of Forkhead Box M1 transcription factor reduces malignancy in laryngeal squamous carcinoma cells. Asian Pac J Cancer Prev, 12, 1785-8.
- Chi P, Chen Y, Zhang L, et al (2010). ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature, 467, 849-53. https://doi.org/10.1038/nature09409
- Chung CH, Bernard PS, Perou CM (2002). Molecular portraits and the family tree of cancer. Nat Genet, 32, S533-40. https://doi.org/10.1038/ng1038
- Clay CE, Namen AM, Atsumi G, et al (1999). Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis, 20, 1905-11. https://doi.org/10.1093/carcin/20.10.1905
- Crawford HC, Fingleton B, Gustavson MD, et al (2001). The PEA3 subfamily of Ets transcription factors synergizes with beta-catenin-LEF-1 to activate matrilysin transcription in intestinal tumors. Mol Cell Biol, 21, 1370-83. https://doi.org/10.1128/MCB.21.4.1370-1383.2001
- Cui JW, Li Y, Wang C, et al (2012). Knockdown of a proliferationinducing ligand (PRIL) suppresses the proliferation of gastric cancer cells. Asian Pac J Cancer Prev, 13, 633-6. https://doi.org/10.7314/APJCP.2012.13.2.633
- Dowdy SC, Mariani A, Janknecht R (2003). HER2/Neu- and TAK1-mediated up-regulation of the transforming growth factor beta inhibitor Smad7 via the ETS protein ER81. J Biol Chem, 278, 44377-84. https://doi.org/10.1074/jbc.M307202200
- Fuchs B, Inwards C, Scully SP, et al (2004). hTERT Is highly expressed in Ewing's sarcoma and activated by EWS-ETS oncoproteins. Clin Orthop Relat Res, 426, 64-8. https://doi.org/10.1097/01.blo.0000141385.77071.8d
- Fuchs B, Inwards CY, Janknecht R (2003). Upregulation of the matrix metalloproteinase-1 gene by the Ewing's sarcoma associated EWS-ER81 and EWS-Fli-1 oncoproteins, c-Jun and p300. FEBS Lett, 553, 104-8. https://doi.org/10.1016/S0014-5793(03)00984-0
- Fuchs B, Inwards CY, Janknecht R (2004). Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma. Clin Cancer Res, 10, 1344-53. https://doi.org/10.1158/1078-0432.CCR-03-0038
- Galang CK, Muller WJ, Foos G, et al (2004). Changes in the expression of many Ets family transcription factors and of potential target genes in normal mammary tissue and tumors. J Biol Chem, 279, 11281-92. https://doi.org/10.1074/jbc.M311887200
- Goel A, Janknecht R (2003). Acetylation-mediated transcriptional activation of the ETS protein ER81 by p300, P/CAF, and HER2/Neu. Mol Cell Biol, 23, 6243-54. https://doi.org/10.1128/MCB.23.17.6243-6254.2003
- Goueli BS, Janknecht R (2004). Upregulation of the catalytic telomerase subunit by the transcription factor ER81 and oncogenic HER2/Neu, Ras, or Raf. Mol Cell Biol, 24, 25-35. https://doi.org/10.1128/MCB.24.1.25-35.2004
- Ha SA, Lee YS, Shin SM, et al (2009). Oncoprotein HCCR-1 expression in breast cancer is well correlated with known breast cancer prognostic factors including the HER2 overexpression, p53 mutation, and ER/PR status. BMC Cancer, 9, 51. https://doi.org/10.1186/1471-2407-9-51
- Higashino F, Yoshida K, Fujinaga Y, et al (1993). Isolation of a cDNA encoding the adenovirus E1A enhancer binding protein: a new human member of the ets oncogene family. Nucleic Acids Res, 21, 547-53. https://doi.org/10.1093/nar/21.3.547
- Holbro T, Civenni G, Hynes NE (2003). The ErbB receptors and their role in cancer progression. Exp Cell Res, 284, 99-110. https://doi.org/10.1016/S0014-4827(02)00099-X
- Jane-Valbuena J, Widlund HR, Perner S, et al (2010). An oncogenic role for ETV1 in melanoma. Cancer Res, 70, 2075-84. https://doi.org/10.1158/0008-5472.CAN-09-3092
- Janknecht R (1996). Analysis of the ERK-stimulated ETS transcription factor ER81. Mol Cell Biol, 16, 1550-6. https://doi.org/10.1128/MCB.16.4.1550
- Janknecht R (2004). On the road to immortality: hTERT upregulation in cancer cells. FEBS Lett, 564, 9-13. https://doi.org/10.1016/S0014-5793(04)00356-4
- Janknecht R (2005). EWS-ETS oncoproteins: the linchpins of Ewing tumors. Gene, 363, 1-14. https://doi.org/10.1016/j.gene.2005.08.007
- Janknecht R, Ernst WH, Pingoud V, et al (1993). Activation of ternary complex factor Elk-1 by MAP kinases. EMBO J, 12, 5097-104.
- Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
- Jeon IS, Davis JN, Braun BS, et al (1995). A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene, 10, 1229-34.
- Lu WC, Liu YN, Kang BB, et al (2003). Trans-activation of heparanase promoter by ETS transcription factors. Oncogene, 22, 919-23. https://doi.org/10.1038/sj.onc.1206201
- Lv M, Li B, Li Y, et al (2011). Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China. Asian Pac J Cancer Prev, 12, 2411-7.
- Monte D, Baert JL, Laget MP, et al (1995). Transcription factors of the PEA3 group in mammary cancer. Ann Endocrinol, 56, 547-51 (in French).
- Monte D, Coutte L, Baert JL, et al (1995). Molecular characterization of the ets-related human transcription factor ER81. Oncogene, 11, 771-9.
- Netzer S, Leenders F, Dumont P, et al (2002). Ectopic expression of the ets transcription factor ER81 in transgenic mouse mammary gland enhances both urokinase plasminogen activator and stromelysin-1 transcription. Transgenic Res, 11, 123-31. https://doi.org/10.1023/A:1015248525364
- Papoutsopoulou S, Janknecht R (2000). Phosphorylation of ETS transcription factor ER81 in a complex with its coactivators CREB-binding protein and p300. Mol Cell Biol, 20, 7300-10. https://doi.org/10.1128/MCB.20.19.7300-7310.2000
- Shepherd TG, L Kockeritz, MR Szrajber, et al. (2001). The pea3 subfamily ets genes are required for HER2/Neu-mediated mammary oncogenesis. Curr Biol, 11, 1739-48. https://doi.org/10.1016/S0960-9822(01)00536-X
- Shin SD, Bosc G, Ingle JN, et al (2008). Rcl is a novel ETV1/ ER81 target gene upregulated in breast tumors. J Cell Biochem, 105, 866-74. https://doi.org/10.1002/jcb.21884
- Shin S, Kim TD, Jin F, et al (2009). Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81. Cancer Res, 69, 8102-10. https://doi.org/10.1158/0008-5472.CAN-09-0941
- Subik K, Lee JF, Baxter L, et al (2010). The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer (Auckl), 4, 35-41.
- Tomlins SA, Laxman B, Dhanasekaran SM, et al (2007). Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature, 448, 595-9. https://doi.org/10.1038/nature06024
- Vageli D, Ioannou MG, Koukoulis GK (2009). Transcriptional activation of hTERT in breast carcinomas by the Her2-ER81-related pathway. Oncol Res, 17, 413-23. https://doi.org/10.3727/096504009788912507
- Wang Y, Wang L, Chen Y, et al (2011). ER81 Expression in Breast Cancers and Hyperplasia. Patholog Res Int, 2011, 980513.
- Yu T, Hou F, Liu M, et al (2012). Norcantharidin antiangiogenesis activity possibly through an endothelial cell pathway in human colorectal cancer. Asian Pac J Cancer Prev, 13, 499-503. https://doi.org/10.7314/APJCP.2012.13.2.499
- Altered expression of ETV1 and its contribution to tumorigenic phenotypes in gastrointestinal stromal tumors vol.32, pp.3, 2014, https://doi.org/10.3892/or.2014.3281
- Targeting Of miR9/NOTCH1 Interaction Reduces Metastatic Behavior in Triple-negative Breast Cancer vol.86, pp.5, 2015, https://doi.org/10.1111/cbdd.12584
- MicroRNA-340 inhibits the migration, invasion, and metastasis of breast cancer cells by targeting Wnt pathway vol.37, pp.7, 2016, https://doi.org/10.1007/s13277-015-4513-9
- Transcriptional Analysis of Apoptotic Cerebellar Granule Neurons Following Rescue by Gastric Inhibitory Polypeptide vol.15, pp.4, 2014, https://doi.org/10.3390/ijms15045596